ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

Letter to the Editor: IOM Study Welcome For “Omic” Research

October 29, 2010

NIH Deputy Director Ruth Kirschstein Plans Transition To Senior Advisor

October 4, 2002

In Brief: Lasker Foundation Will Not Make 1990 Awards; Michigan Cancer Elects Fischer Vice Chairman

March 2, 1990

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

NCI Developing Plan To Replace Research Contracts At Academic Institutions With “Program Grants”

February 22, 1974

Clinical Cooperative Groups Asked To Develop Tamoxifen Prevention Trial; CGOPs To Participate

July 6, 1990